Neuromod Welcomes New Leadership to Enhance Tinnitus Treatment Strategy
Neuromod Devices, a prominent name in medical technology, has recently welcomed Joe Ghiz as its Chief Commercial Officer (CCO) and Shannon Basham as Vice President of Channel Development. These appointments come at a pivotal moment for the company, as it aims to expand the accessibility of Lenire, an innovative device designed for tinnitus treatment.
Joe Ghiz brings an impressive background to Neuromod, having held significant leadership positions internationally at Align Technology, the company behind the popular Invisalign product, and at Johnson & Johnson. His track record includes spearheading global sales initiatives and marketing strategies that have significantly boosted companies and established them as leaders in their respective markets. By joining Neuromod, Ghiz is set to leverage his extensive experience in creating and executing successful commercial strategies that align with the company’s mission to provide breakthrough solutions for the 740 million people worldwide suffering from tinnitus.
In a statement announcing his new role, Ghiz expressed his excitement about joining Neuromod during such a transformative time. "Lenire has already changed the lives of thousands suffering from tinnitus, and I look forward to working with the Neuromod team to enhance our commercial strategy. My goal is to ensure that many more health professionals can provide this life-changing treatment to patients in need," he said.
Shannon Basham also joins Neuromod with over two decades of experience in the audiology sector. Prior to her appointment, she served as Senior Director of Audiology at Sonova Group, where she played a crucial role in shaping market strategies and developing training programs focused on Phonak and Unitron products. Her depth of knowledge and experience in channel development will be instrumental as she works to strengthen Neuromod’s distribution channels, thereby enhancing the reach of Lenire.
Basham underscored her enthusiasm about her new position, noting, "I am eager to contribute to Neuromod's mission during this crucial growth phase and to help build a solid foundation that will support the delivery of our innovative tinnitus treatment."
Dr. Ross O'Neill, CEO of Neuromod, highlighted the importance of these new appointments, remarking, "With strong clinical data, global regulatory approvals, and expanding commercial adoption, Neuromod is poised for rapid expansion. The leadership and expertise that Joe and Shannon bring will greatly accelerate our efforts in addressing the needs of tinnitus patients worldwide."
Neuromod Devices is at the forefront of developing neuromodulation technologies to meet the clinical needs of patients with tinnitus. Their flagship product, Lenire, is a non-invasive bimodal neuromodulation device that promises substantial relief for tinnitus sufferers and is prescribed by qualified healthcare professionals following a comprehensive hearing evaluation. The device uniquely combines sound stimulation with a tongue surface stimulation, delivered through its proprietary Tonguetip® device. Lenire is supported by extensive clinical trials validating its safety and efficacy, and it has attained a "De Novo" FDA authorization, making it the first system of its kind available in the market.
The inclusion of Ghiz and Basham further solidifies Neuromod's commitment to revolutionizing tinnitus treatment, a condition that currently impacts millions globally. As the company continues to expand and innovate, it aims to provide accessible solutions that have been scientifically backed and clinically validated, ultimately transforming the lives of countless patients suffering from this challenging ailment.
For more information about Neuromod Devices and their groundbreaking tinnitus treatment, visit their official website at www.neuromod.com.
Joe Ghiz brings an impressive background to Neuromod, having held significant leadership positions internationally at Align Technology, the company behind the popular Invisalign product, and at Johnson & Johnson. His track record includes spearheading global sales initiatives and marketing strategies that have significantly boosted companies and established them as leaders in their respective markets. By joining Neuromod, Ghiz is set to leverage his extensive experience in creating and executing successful commercial strategies that align with the company’s mission to provide breakthrough solutions for the 740 million people worldwide suffering from tinnitus.
In a statement announcing his new role, Ghiz expressed his excitement about joining Neuromod during such a transformative time. "Lenire has already changed the lives of thousands suffering from tinnitus, and I look forward to working with the Neuromod team to enhance our commercial strategy. My goal is to ensure that many more health professionals can provide this life-changing treatment to patients in need," he said.
Shannon Basham also joins Neuromod with over two decades of experience in the audiology sector. Prior to her appointment, she served as Senior Director of Audiology at Sonova Group, where she played a crucial role in shaping market strategies and developing training programs focused on Phonak and Unitron products. Her depth of knowledge and experience in channel development will be instrumental as she works to strengthen Neuromod’s distribution channels, thereby enhancing the reach of Lenire.
Basham underscored her enthusiasm about her new position, noting, "I am eager to contribute to Neuromod's mission during this crucial growth phase and to help build a solid foundation that will support the delivery of our innovative tinnitus treatment."
Dr. Ross O'Neill, CEO of Neuromod, highlighted the importance of these new appointments, remarking, "With strong clinical data, global regulatory approvals, and expanding commercial adoption, Neuromod is poised for rapid expansion. The leadership and expertise that Joe and Shannon bring will greatly accelerate our efforts in addressing the needs of tinnitus patients worldwide."
Neuromod Devices is at the forefront of developing neuromodulation technologies to meet the clinical needs of patients with tinnitus. Their flagship product, Lenire, is a non-invasive bimodal neuromodulation device that promises substantial relief for tinnitus sufferers and is prescribed by qualified healthcare professionals following a comprehensive hearing evaluation. The device uniquely combines sound stimulation with a tongue surface stimulation, delivered through its proprietary Tonguetip® device. Lenire is supported by extensive clinical trials validating its safety and efficacy, and it has attained a "De Novo" FDA authorization, making it the first system of its kind available in the market.
The inclusion of Ghiz and Basham further solidifies Neuromod's commitment to revolutionizing tinnitus treatment, a condition that currently impacts millions globally. As the company continues to expand and innovate, it aims to provide accessible solutions that have been scientifically backed and clinically validated, ultimately transforming the lives of countless patients suffering from this challenging ailment.
For more information about Neuromod Devices and their groundbreaking tinnitus treatment, visit their official website at www.neuromod.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.